CEO: Alain Huriez

Advent Contact: Raj Parekh

Novel Platform for modulating Vasculitis

Tridek-One is researching and developing new modalities for modulating neutrophil and leukocyte-associated vascular damage in a range of auto-immune diseases, with an initial focus on ANCA.

Advent invested in the Seed round in 2018.

Back